Treatment of Intrabony Defects With L-PRF Membrane With or Without Collagen Membranes

NCT ID: NCT05496608

Last Updated: 2022-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For patients having periodontal intrabony lesions, three treatment modalities were executed to evaluate the effect of protecting Leukocyte rich -Platelet Rich Fibrin harvests (applied in the bony defects) with resorbable collagen membranes. Clinical Outcomes recorded were the Plaque index (PI), Gingival index (GI), probing depth reduction (PD), Clinical attachment level (CAL), and radiographic defect depth changes.

For the biochemical evaluation: levels of PDGF-BB and VEGF obtained from crevicular fluid by Perio-Paper strips were assessed using ELIZA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Patients having 2-3 osseous bony wall infrabony periodontal lesions are enrolled in the present study. They have to be free from any systemic disease that contraindicates periodontal surgeries.
* Baseline data are obtained including the GI, PI, PD, CAL and preoperative paralleling periapical radiographs.
* Full thickness mucoperiosteal flaps are elevated and thorough debridement of the periodontal bony defect is performed.
* for OFD group; following debridement and saline irrigation, wound closure proceeds.
* for the L-PRF group; L-PRF is prepared and applied within the defect before primary closure.
* for the L-PRF + CM: similar procedure like the second group is performed but with an additional protective layer of collagen membrane on top of the defect before wound closure.
* from the second day postoperative; Periopaper strips are used to obtain a crevicular fluid sample from the sulcus
* At 6 months postoperative: the same baseline clinical measurements are obtained.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Bone Loss Periodontal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
* The clinical data (Gingival index, Plaque index, PPD, CAL) were collected by a blinded single operator at the university outpatient clinic.
* The biochemical analysis: The biochemist received the filter papers with a label for group letter and patient number. She was didn't know which intervention was carried out for any of the samples.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Flap Debridement

Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion

Group Type PLACEBO_COMPARATOR

OFD

Intervention Type PROCEDURE

Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

L-PRF

Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion followed by application of the L-PRF within the bony defect

Group Type ACTIVE_COMPARATOR

L-PRF

Intervention Type PROCEDURE

a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.

OFD

Intervention Type PROCEDURE

Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

L-PRF + CM

Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion followed by application of the L-PRF within the bony defect and coverage with collagen xenogeneic membrane

Group Type ACTIVE_COMPARATOR

L-PRF

Intervention Type PROCEDURE

a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.

OFD

Intervention Type PROCEDURE

Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

CM

Intervention Type PROCEDURE

Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-PRF

a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.

Intervention Type PROCEDURE

OFD

Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

Intervention Type PROCEDURE

CM

Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Leukocyte platelet rich fibrin Open flap Debridement Collagen membrane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Minimum of one interproximal pocket probing depth of ≥6 mm and/or ≥5 mm CAL after 4 weeks from phase I execution
* 2 or 3 osseous wall interproximal intrabony defects that are ≥3mm in depth

Exclusion Criteria

* Systemic diseases or conditions that contraindicate periodontal surgeries and/or affect the formed elements of the blood
* Patients who received antibiotic therapy and/or anti-inflammatory drug within the past 6 months
* Vulnerable groups
* Interdental craters and 1 wall osseous defects
* Active periapical pathosis
Minimum Eligible Age

30 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Future University in Egypt

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ramy Mubarak Hussein

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed Gamal, P.H.D

Role: STUDY_CHAIR

Professor of periodontology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ainshams University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Mubarak R, Adel-Khattab D, Abdel-Ghaffar KA, Gamal AY. Adjunctive effect of collagen membrane coverage to L-PRF in the treatment of periodontal intrabony defects: a randomized controlled clinical trial with biochemical assessment. BMC Oral Health. 2023 Sep 4;23(1):631. doi: 10.1186/s12903-023-03332-0.

Reference Type DERIVED
PMID: 37667213 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ainshams University

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Growth Factors Release of PRF and PRGF
NCT02447510 COMPLETED PHASE3